Cargando…
Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer
PIM and PI3K/mTOR pathways are often dysregulated in prostate cancer, and may lead to decreased survival, increased metastasis and invasion. The pathways are heavily interconnected and act on a variety of common effectors that can lead to the development of resistance to drug inhibitors. Most curren...
Autores principales: | Luszczak, Sabina, Simpson, Benjamin S., Stopka-Farooqui, Urszula, Sathyadevan, Vignesh Krishna, Echeverria, Lina M. Carmona, Kumar, Christopher, Costa, Helena, Haider, Aiman, Freeman, Alex, Jameson, Charles, Ratynska, Marzena, Ben-Salha, Imen, Sridhar, Ashwin, Shaw, Greg, Kelly, John D., Pye, Hayley, Gately, Kathy A., Whitaker, Hayley C., Heavey, Susan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7463239/ https://www.ncbi.nlm.nih.gov/pubmed/32873828 http://dx.doi.org/10.1038/s41598-020-71263-9 |
Ejemplares similares
-
Author Correction: Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer
por: Luszczak, Sabina, et al.
Publicado: (2020) -
PIM kinase inhibition: co-targeted therapeutic approaches in prostate cancer
por: Luszczak, Sabina, et al.
Publicado: (2020) -
Maintenance BEZ235 Treatment Prolongs the Therapeutic Effect of the Combination of BEZ235 and Radiotherapy for Colorectal Cancer
por: Chen, Yu-Hsuan, et al.
Publicado: (2019) -
AUM302, a novel triple kinase PIM/PI3K/mTOR inhibitor, is a potent in vitro pancreatic cancer growth inhibitor
por: Ingle, Komala, et al.
Publicado: (2023) -
NVP-BEZ235 synergizes cisplatin sensitivity in osteosarcoma
por: Huang, Jin-Cheng, et al.
Publicado: (2017)